- Home
- KAPA vs BIAF Comparison
KAPA vs BIAF Comparison
Compare KAPA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAPA
- BIAF
- Stock Information
- Founded
- KAPA 2013
- BIAF 2014
- Country
- KAPA United States
- BIAF United States
- Employees
- KAPA N/A
- BIAF N/A
- Industry
- KAPA
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KAPA
- BIAF Health Care
- Exchange
- KAPA NYSE
- BIAF Nasdaq
- Market Cap
- KAPA 21.3M
- BIAF 20.4M
- IPO Year
- KAPA 2024
- BIAF 2022
- Fundamental
- Price
- KAPA $1.45
- BIAF $1.45
- Analyst Decision
- KAPA Strong Buy
- BIAF Strong Buy
- Analyst Count
- KAPA 1
- BIAF 1
- Target Price
- KAPA $9.00
- BIAF $6.00
- AVG Volume (30 Days)
- KAPA 203.7K
- BIAF 182.5K
- Earning Date
- KAPA 11-23-2024
- BIAF 11-12-2024
- Dividend Yield
- KAPA N/A
- BIAF N/A
- EPS Growth
- KAPA N/A
- BIAF N/A
- EPS
- KAPA N/A
- BIAF N/A
- Revenue
- KAPA N/A
- BIAF $7,315,883.00
- Revenue This Year
- KAPA N/A
- BIAF $302.41
- Revenue Next Year
- KAPA N/A
- BIAF $15.00
- P/E Ratio
- KAPA N/A
- BIAF N/A
- Revenue Growth
- KAPA N/A
- BIAF 30185.99
- 52 Week Low
- KAPA $1.22
- BIAF $1.15
- 52 Week High
- KAPA $4.00
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- KAPA N/A
- BIAF 37.60
- Support Level
- KAPA N/A
- BIAF $1.84
- Resistance Level
- KAPA N/A
- BIAF $2.24
- Average True Range (ATR)
- KAPA 0.00
- BIAF 0.21
- MACD
- KAPA 0.00
- BIAF -0.06
- Stochastic Oscillator
- KAPA 0.00
- BIAF 19.24
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.